title: Cholecystokinin octapeptide significantly suppresses collagen-induced arthritis in mice by inhibiting Th17 polarization primed by dendritic cells.
abstract: Cholecystokinin octapeptide (CCK-8) is a neuropeptide, and is shown to be a potent immunomodulator with predominant anti-inflammatory effects. Although the regulatory effect of CCK-8 on macrophages and B cells has been defined, the effect of CCK-8 on dendritic cells (DCs) and T cells is not well understood. In this study, we showed that CCK-8 reduced the expression of CD80, CD86, and MHCII on DCs. Moreover, CCK-8 promoted Th1 and inhibited Th17 polarization by increasing the production of IL-12 and decreasing the production of IL-6 and IL-23 on DCs in vitro and in vivo. In addition, intraperitoneal administration of CCK-8 to mice with collagen-induced arthritis (CIA) was found to effectively reduce the incidence of arthritis, delay its onset and prevent the occurrence of joint damage. Collectively, these results suggest that CCK-8 significantly suppresses the incidence and severity of CIA in mice, through the inhibition of DC mediated Th17 polarization.
authors: Institute of Basic Medicine, Hebei Medical University, Zhongshan East Road 361, Shijiazhuang, Hebei Province, P R China.
authors: Qiaoxia
authors: Q
authors: Li
authors: Dongyan
authors: D
authors: Han
authors: Bin
authors: B
authors: Cong
authors: Baoen
authors: B
authors: Shan
authors: Jingge
authors: J
authors: Zhang
authors: Haiying
authors: H
authors: Chen
authors: Chunling
authors: C
authors: Ma
authors: Surabhi S
authors: SS
authors: Liyanage
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000032:analysis / Q000276:immunology; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D002454:Cell Differentiation; D024043:Collagen Type II / Q000008:administration & dosage / Q000009:adverse effects; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D007274:Injections, Intraperitoneal; D018664:Interleukin-12 / Q000096:biosynthesis; D053759:Interleukin-23 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D007596:Joints / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008811:Mice, Inbred DBA; D016133:Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology*; D012844:Sincalide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018417:Th1 Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D058504:Th17 Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism
chemical_list: C090019:8-sulfocholecystokinin octapeptide; D015703:Antigens, CD; D024043:Collagen Type II; D053759:Interleukin-23; D015850:Interleukin-6; D018664:Interleukin-12; D012844:Sincalide